content: SECURITIES AND EXCHANGE COMMISSION
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
       Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934
  
                            Date of Report: March 1, 2002
                          (Date of earliest event reported)
  
                                 IMMUNOMEDICS, INC.
               (Exact name of Registrant as specified in its Charter)
  
                                      Delaware
                   (State or other jurisdiction of incorporation)
  
                    0-12104                                61-1009366
            (Commission File No.)              IRS Employer Identification Number)
  
                 300 American Road, Morris Plains, New Jersey 07950
                 (Address of principal executive offices) (Zip Code)
  
                 Registrant's telephone number, including area code:
                                   (973) 605-8200
  
                                         N/A
            (Former name or former address, if changed since last report)
  
                      ----------------------------------------
  
  
                                Item 5. Other Events
  
  David  M.  Goldenberg,  Sc.D.,  M.D.,  Chairman  of the  Board of  Directors  of
  Immunomedics, Inc., has advised the Company that he entered into a written stock
  selling plan in accordance with SEC Rule 10b5-1, pursuant to which he intends to
  gradually liquidate a small portion  (approximately 0.3%) of his holdings in the
  Company.  The plan calls for daily sales of stock in amounts  dependent upon the
  prevailing  market price. The amounts sold could be zero, 5,000 shares, or up to
  20,000 shares per month,  depending on market  conditions.  Selling according to
  this plan will  commence  March 1, 2002 and will  continue  for one year  unless
  sooner terminated.
  
                                     SIGNATURES
  
  Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized:
  
                                 IMMUNOMEDICS, INC.
  
  
  Date:  March 4, 2002
  
  
      /S/ Gerard G. Gorman
  By: -----------------------------------------
      Gerard G. Gorman, Chief Financial Officer
  
  
                      ----------------------------------------
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "mar8k2002.txt", "description": "MARCH 1, 2002", "secsgml_size_bytes": 2356}]
metadata_filer: {"company-data": {"conformed-name": "IMMUNOMEDICS INC", "cik": "0000722830", "assigned-sic": "2835", "irs-number": "611009366", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12104", "film-number": "02565847"}, "business-address": {"street1": "300 AMERICAN RD", "city": "MORRIS PLAINS", "state": "NJ", "zip": "07950", "phone": "9736058200"}, "mail-address": {"street1": "300 AMERICAN ROAD", "city": "MORRIS PLAINS", "state": "NJ", "zip": "07950"}}
text: SECURITIES AND EXCHANGE COMMISSION
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
       Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934
  
                            Date of Report: March 1, 2002
                          (Date of earliest event reported)
  
                                 IMMUNOMEDICS, INC.
               (Exact name of Registrant as specified in its Charter)
  
                                      Delaware
                   (State or other jurisdiction of incorporation)
  
                    0-12104                                61-1009366
            (Commission File No.)              IRS Employer Identification Number)
  
                 300 American Road, Morris Plains, New Jersey 07950
                 (Address of principal executive offices) (Zip Code)
  
                 Registrant's telephone number, including area code:
                                   (973) 605-8200
  
                                         N/A
            (Former name or former address, if changed since last report)
  
                      ----------------------------------------
  
                                Item 5. Other Events
  
  David  M.  Goldenberg,  Sc.D.,  M.D.,  Chairman  of the  Board of  Directors  of
  Immunomedics, Inc., has advised the Company that he entered into a written stock
  selling plan in accordance with SEC Rule 10b5-1, pursuant to which he intends to
  gradually liquidate a small portion  (approximately 0.3%) of his holdings in the
  Company.  The plan calls for daily sales of stock in amounts  dependent upon the
  prevailing  market price. The amounts sold could be zero, 5,000 shares, or up to
  20,000 shares per month,  depending on market  conditions.  Selling according to
  this plan will  commence  March 1, 2002 and will  continue  for one year  unless
  sooner terminated.
  
                                     SIGNATURES
  
  Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized:
  
                                 IMMUNOMEDICS, INC.
  
  Date:  March 4, 2002
  
      /S/ Gerard G. Gorman
  By: -----------------------------------------
      Gerard G. Gorman, Chief Financial Officer
  
                      ----------------------------------------